Chinese medicinal formula Guanxin Shutong capsule protects the heart against oxidative stress and apoptosis induced by ischemic myocardial injury in rats

YANJUN CAO¹, XU HE¹, FENG LUI¹, ZHUANGZHUANG HUANG² and YANMIN ZHANG¹

¹School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061; ²School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China

Received September 14, 2013; Accepted January 30, 2014

DOI: 10.3892/etm.2014.1540

Abstract. Guanxin Shutong capsule (GXSTC) is a Chinese medicinal formula that has been used clinically for the treatment of chest pain, depression, palpitation and cardiovascular diseases in China for almost 10 years. The aim of the present study was to investigate the protective mechanisms against oxidative stress and apoptosis that GXSTC exhibits in the hearts of rats with myocardial ischemia (MI). Infarct size and the levels of marker enzymes, including serum creatine kinase-isoenzyme (CK-MB), lactate dehydrogenase (LDH) and glutamate oxaloacetic transaminase (GOT), as well as the levels of nitric oxide (NO) and NO synthase (NOS) in the heart were measured by biochemical analysis assays. Levels of the antioxidants superoxide dismutase (SOD), catalase (CATA), and glutathione (GSH), and the oxidative stress marker malondialdehyde (MDA), were also determined. Following a 6-week period of ischemia, myocardial apoptosis, as well as the protein and mRNA expression of NADPH oxidase, was evaluated. Myocardial NADPH oxidase activity was measured by protein expression of p47phox and gp91phox using western blot analysis and mRNA expression of p22phox, p47phox, p67phox and gp91phox using reverse transcription polymerase chain reaction. The results showed that daily oral treatment of the rats with GXSTC reduced infarct size, myocardial apoptosis, the levels of serum MDA, LDH, CK-MB and GOT and heart GOT, and increased the activities of total SOD, CATA, NOS and the levels of NO and GSH compared with those in vehicle-treated MI model rats. Administration of GXSTC for 6 weeks also reduced the mRNA expression of the NADPH oxidase subunits p47phox and gp91phox protein, as well as the expression of Bax and caspase-3 proteins. By contrast, Bcl-2 protein expression increased. In conclusion, the results demonstrate that GXSTC attenuates myocardial injury via antioxidative and antiapoptotic effects.

Introduction

Ischemic heart disease (IHD), which leads to myocardial infarction (MI), is a major clinical problem. Numerous patients continue to present with angina and myocardial ischemia (1). A pathological study has shown that ischemic apoptosis plays a critical role in acute MI (2) and apoptosis and necrosis have been reported to be associated with this clinical condition (3). In cardiac myocytes in vitro, the inhibition of NADPH oxidase reduces apoptosis (4). In previous years, studies have found that a number of traditional plants and their extracts have antioxidative effects on IHD (5,6).

IHD is the principal etiology for the development of congestive heart failure. Sustained ischemia causes several types of damage to cardiac tissues, including cardiomyocyte apoptosis (7). Heart failure following MI is a common clinical problem and has a poor prognosis. It has been demonstrated that free radicals are involved in the pathogenesis of heart failure, subsequent to MI. Changes in myocardial antioxidant levels, as well as oxidative stress, have been observed in the surviving myocardium of rats subjected to MI (8,9). The early stages of MI are accompanied by a significant increase in oxidative stress and lipid peroxidation, with significant reductions in glutathione (GSH), catalase (CATA) and superoxide dismutase (SOD) levels. The mechanism of action of Bcl-2 in the prevention of apoptosis has also been hypothesized to be mediated by an antioxidant pathway. Reactive oxygen species (ROS) have been implicated in myocardial hypertrophy, apoptosis, contractile dysfunction and fibrosis (3).

Traditional Chinese medicine has been shown to have specific prospective therapeutic effects on IHD. Guanxin Shutong capsule (GXSTC) is a widely used Chinese medicinal formula, which is clinically administered for palpitations, restlessness, short breath, fatigue, dizziness and chest pain, promoting blood circulation, removing blood stasis (9) and protecting against cardiovascular diseases (10,11). GXSTC contains five traditional Chinese drugs: Choeorospondiatis, Salvia miltiorrhiza, lilac, borneol and tabasheer. Studies have
indicated that lilac possesses antioxidant properties (10) and choerospordiatis and *Salvia miltiorrhiza* exhibit anti-ischemic therapeutic effects (12), as well as the ability to scavenge active oxygen free radicals (13).

Experimental and clinical studies have indicated that GXSTC has various cardiovascular pharmacological effects. However, there is little information available concerning the antioxidative mechanisms of GXSTC. Therefore, the purpose of the present study was to evaluate whether orally administered CXSTC protects the heart against oxidative stress and apoptosis in rats with MI.

Materials and methods

**Surgical preparation of the animals.** Experimental procedures and protocols on animals were approved by the Ethics Committee of Xi'an Jiaotong University for Animal Research (Xi'an, China). Male Wistar rats, weighing 290-310 g (purchased from school of medicine, Xi'an Jiaotong University, Xi'an, China), were anesthetized by the intraperitoneal injection of 35 mg/kg pentobarbital sodium. Following intratracheal intubation, a left thoracotomy was performed under volume-controlled mechanical ventilation. The heart was raised from the thorax and a ligature with a 6-0 Prolene suture was placed around the proximal left anterior descending coronary artery. The chest was then closed. The same surgical procedures were performed in sham-operated rats, with the exception that the suture around the coronary artery was not tied. Samples were collected from the marginal region around the infarction as samples of infarcted sites.

GXSTC consists of five traditional Chinese drugs: 57.1% choerospordiatis, 28.6% *Salvia miltiorrhiza*, 7.1% lilac, 3.6% borneol and 3.6% tabasheer. GXSTC was provided by Buchang Pharmaceuticals (batch no. 20120125; Xi'an, China). Following removal of the capsules, the Guanxin Shutong powder was dissolved in 40 mg/ml aseptic sodium carboxymethylcellulose (CMC-Na; 0.5%). Within 24 h after modeling, the solution was administered intragastrically each day at 0.2 g/kg body weight (GXSTC). After 6 weeks of treatment, 24-h urine samples and the sham surgery and MI + vehicle groups (8 rats for each group). After 6 weeks of treatment, 24-h urine samples and blood were harvested. Following decapitation, the hearts were removed, snap-frozen in liquid nitrogen and stored at -80°C until required for processing for protein or mRNA extraction.

**Determination of the infarct size.** The heart tissue was washed with PBS three times. Sections were sliced and then incubated for 10 min in nitrotetrazolium blue chloride for pathological examination. Photographs were captured and the infarct size was measured with Image-Pro Plus software (MediaCybernetics, Inc., Rockville, MD, USA). Ischemic and left ventricular areas were determined in five slices of each heart tissue sample. The ischemic risk area ratio was defined as a percentage and calculated as follows: Total ischemic area/total left ventricular area x 100.

**Antioxidant assays.** To determine the total SOD and CATA activities, as well as the malondialdehyde (MDA) and GSH levels, blood was sampled from the abdominal aorta and serum was obtained following centrifugation at 3,000 x g for 10 min. The MDA and GSH levels, and SOD and CATA activities, were measured spectrophotometrically using diagnostic kits (Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer’s instructions.

**Determination of serum creatine kinase-isoenzyme (CK-MB), serum lactate dehydrogenase (LDH) and serum glutamate oxaloacetic transaminase (SGOT).** Blood was sampled from the abdominal aorta and serum was obtained by centrifugation at 3,000 x g for 10 min. CK-MB, LDH and SGOT levels were determined spectrophotometrically at 660, 450 and 510 nm, respectively, using diagnostic kits (Jiancheng Bioengineering Institute), according to the manufacturer’s instructions.

**Determination of heart SOD, GOT, nitric oxide (NO) and NO synthase (NOS).** Heart tissue was homogenized in ice-cold 0.9% saline solution and centrifuged at 600 x g for 10 min. The supernatant was used to determine SOD, GOT, NO and NOS levels, which were measured spectrophotometrically using diagnostic kits (Jiancheng Bioengineering Institute) according to the manufacturer’s instructions.

**mRNA expression of NADPH oxidase subunits.** The mRNA expression levels of p22phox, p47phox, gp91phox and p67phox in the renal cortical tissues were quantitatively analyzed by reverse transcription polymerase chain reaction (RT-PCR), as described previously (14,15). Primer sequences for the analysis of p22phox, p47phox, p67phox, gp91phox and GAPDH mRNA are shown in Table I. GAPDH was measured as an invariant housekeeping gene for an internal control. Amplified cDNA bands were detected by Goldview staining (RuiTaibio, Beijing, China) and the quantities of mRNA were evaluated using the Gene Genius imaging system (Syngene, Cambridge, UK).

**Determination of Bcl-2, Bax, caspase-3, gp91phox and p47phox protein expression.** Rabbit monoclonal antibodies against Bcl-2, Bax, p47phox (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), gp91phox and caspase-3 (Epitomics, Burlingame, CA, USA), were used to determine the protein expression levels of gp91phox, p47phox, Bcl-2 and Bax by western blot analysis, as described previously (16,17).

**Statistical analysis.** All data are expressed as mean ± SD. Statistical analysis was performed by Student’s t-test or one-way ANOVA, followed by a Tukey’s multiple comparison test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Effect of GXSTC on infarct size.** The ischemic risk area ratio was 33.93±6.56% in the MI + vehicle group. Treatment with GXSTC at doses of 0.1 and 0.2 g/kg body weight resulted in dose-dependent reductions in infarct size, with ischemic risk area ratios of 23.45±4.67 and 17.82±5.89%, respectively. Significant differences were observed in the ratios between the MI + vehicle and GXSTCL and GXSTCH groups (Table II).
Antioxidant assays. The serum SOD, GSH and CATA levels of the MI + vehicle group were significantly decreased (1,560.90±130.02, 149.80±18.95 and 15.18±1.16 U/ml, respectively), while the serum MDA level was significantly increased (9.8 ± 0.93 nmol/ml) compared with the corresponding levels in the sham-operated rats (Fig. 1). The GXSTCL and GXSTCH groups showed significantly reduced serum levels of MDA (6.86±0.58 and 4.59±0.15 nmol/ml, respectively). By contrast, the levels of SOD, GSH and CATA were increased (to 2,110.8.56±190.94 and 2,300.92±180.49 U/ml; 180.58±18.77

Table II. Effect of GXSTC on the myocardial infarct size following ligature of the left anterior descending coronary artery.

| Group          | Infarct size, cm² | Left ventricular areas, cm² | Infarct-to-left ventricular areas, % |
|----------------|-------------------|-----------------------------|-------------------------------------|
| MI + vehicle   | 1.33±0.29         | 2.59±0.19                   | 33.93±6.56                          |
| Sham           | 0                 | 3.13±0.21                   | 0                                   |
| GXSTCL         | 0.87±0.09         | 2.84±0.13                   | 23.45±4.67a                         |
| GXSTCH         | 0.59±0.06         | 2.72±0.26                   | 17.82±5.89b                         |

Data are presented as mean ± SD (n=12 for each group). *P<0.05 and **P<0.01, vs. MI + vehicle. GXSTC, Guanxin Shutong capsule; GXSTCL, 0.1 g/kg body weight GXSTC; GXSTCH, 0.2 g/kg body weight GXSTC.

Table I. Primers used for p22phox, p47phox, p67phox, gp91phox and GAPDH.

| mRNA     | Primer    | Sequence, 5’-3’ |
|----------|-----------|----------------|
| p22phox  | Sense     | ATGGAGCGGTTGACAGAAG |
|          | Antisense | CGGCAGACATGAGTGAGGAC |
| p47phox  | Sense     | CCATCATTCAGACCTATCG |
|          | Antisense | AACCACCAGCCTCTCG |
| p67phox  | Sense     | CTGTTTGGCTGCTTG |
|          | Antisense | CTTGACGTGAGG |
| gp91phox | Sense     | TAGCATCCATCCGCAATT |
|          | Antisense | CTAAACATACACCTTCATAGC |
| GAPDH    | Sense     | AGTGGCAAATGAGAGTT |
|          | Antisense | GTGGAGTCATACTGGAACA |

Figure 1. Effect of GXSTC on the serum levels of (A) CATA, (B) MDA, (C) SOD and (D) GSH. Sham (sham-operated control; n=12), MI + vehicle (orally administered vehicle; n=12), MI + GXSTCH (orally administered 0.2 g/kg GXSTC; n=12) and MI + GXSTCL (orally administered 0.1 g/kg GXSTC; n=12). *P<0.05 and **P<0.01, vs. MI + vehicle. GXSTC, Guanxin Shutong capsule; CATA, catalase; MDA, malondialdehyde; SOD, superoxide dismutase; GSH, glutathione; MI, myocardial infarction.
The serum levels of CK-MB, LDH and GOT in the MI + vehicle group were increased significantly (1,499.43±180.30, 756.97±35.64 and 66.99±7.06 U/ml, respectively) compared with those in the sham group (Fig. 2). GXSTC at doses of 0.1 and 0.2 g/kg body weight significantly reduced the serum level of CK-MB to 767.85±113.0 and 719.51±140.11 U/ml, respectively (P<0.05; Fig. 2). In addition, GXSTC at both doses significantly decreased SGOT activity.

**Effect of GXSTC on the levels of SOD, GOT, NO and NOS in the heart.** The SOD, NO and NOS levels in the hearts of the MI + vehicle group were significantly decreased whereas the levels of GOT were significantly increased compared with those in the sham-operated rats. In the GXSTCH group, the levels of SOD, NOS and NO (192.81 ± 5.91 and 0.58 ± 0.03 U/mg protein and 11.55 ± 1.05 µg/mg protein, respectively) were significantly increased compared with those in the MI + vehicle group (90.74 ± 2.08 and 0.27 ± 0.01 U/mg protein and 5.84 ± 1.31 µg/mg protein, respectively), whereas the levels of GOT were significantly decreased (from 668.99 ± 70.06 to 480.85 ± 47.11 U/mg protein) (P<0.05, Fig. 3). In addition, the GXSTCL group also showed significantly decreased levels of GOT and increased levels of SOD, NO and NOS in the heart (Fig. 3).

**Effect of GXSTC on the mRNA expression of NADPH oxidase subunits.** MI model rats showed significantly higher p22phox, p47phox, p67phox and gp91phox mRNA expression levels compared with sham-operated rats. Treatment with GXSTC (0.1 and 0.2 g/kg/day) significantly decreased p22phox, p47phox, p67phox and gp91phox mRNA expression (Fig. 4).

**Effect of GXSTC on Bcl-2, Bax and caspase-3 proteins.** The expression of the apoptosis-related proteins Bcl-2, Bax and caspase-3 was studied by western blot analysis. Following the induction of MI, the expression of Bax and caspase-3 markedly
increased, whereas the expression of Bcl-2 decreased (Fig. 5). The MI-induced changes in protein levels were significantly reversed by GXSTC. These results indicated that GXSTC may modulate MI-induced apoptosis via Bcl-2, Bax and caspase-3 proteins (Fig. 5).

**Effect of GXSTC on p47phox and gp91phox proteins.** Western blot analysis was performed on heart homogenates to determine the protein expression levels of the NADPH oxidase subunits gp91phox and p47phox. As shown in Fig. 6, the protein levels of gp91phox and p47phox decreased significantly in the hearts of rats with MI following treatment with GXSTC.

**Discussion**

GXSTC has been reported to be effective in treating MI in animal models and cardiovascular diseases in humans (18). Results of the present study show that GXSTC dose-dependently reduced the size of the infarct caused by ischemic injuries in rats, which is the most reliable indicator of myocardial protection. In addition, it was demonstrated that GXSTC effectively reduced CK-MB, LHD, MDA and SGOT levels in rats with MI, as well as the protein and mRNA expression of NADPH oxidase subunits, but enhanced CAT and SOD activities and GSH levels. Furthermore, protein expression of proapoptotic Bax and caspase-3 were significantly downregulated, while the antiapoptotic protein, Bcl-2, was upregulated in the GXSTC treated groups when compared with the MI + vehicle group.

LDH and CK, which are released into plasma from myocardial tissues, are representative of cardiac cellular damage during MI (19). In the present study, GXSTC significantly increased the serum levels of SOD, indicating that GXSTC possesses a potent antioxidant property. In addition, it was observed that the level of LDH, a biochemical indicator
of cellular damage, was also dose-dependently decreased. Previous studies have shown that acute myocardial ischemia generates numerous free radicals, causing damage to cellular membranes as a result of lipid peroxidation. MDA, formed by the breakdown of lipid peroxides, is often used to quantify the extent of lipid peroxidation (20), whereas serum CK-MB is a cardiac-specific marker of acute MI or an indicator for myocardial tissue injury. The present study demonstrated that GXSTC significantly prevented an increase of serum MDA and CK-MB levels caused by acute ischemic injury, indicating that GXSTC may exert its protective effect against myocardial ischemic injury by reducing lipid peroxidation. Choerospondiatis and *Salvia miltiorrhiza* contain polyphenolic compounds with antioxidant properties, which are considered to provide the pharmacological efficacy against heart ischemia (21). The mechanisms of action of choerospondiatis and *Salvia miltiorrhiza* are distinct and complementary when combined together. Therefore, GXSTC may be synergistic and more effective than the individual components.

MDA, the degradation product of oxygen-derived free radicals and lipid oxidation, reflects the damage caused by ROS (22). Studies on the antioxidant system have shown that changes in SOD activity and MDA levels are always negatively correlated (23). In the present study, GXSTC also increased the serum levels of SOD when administered at doses of 0.1 and 0.2 g/kg/day. However, MDA production was low which implied that the formula may affect the level of endogenous antioxidants and/or oxidative stress. One possible explanation is that the elevated SOD activities resulted in the scavenging of excessive ROS and attenuated lipid peroxidation. GSH is an important cellular reductant that offers protection against free radicals, peroxides and toxic compounds, which is formed from glutathione disulfide (24). The results showed that administration of GXSTC caused a significant increase in GSH levels, which may be due to the compounds present in GXSTC.

Previous animal studies and clinical observations have indicated that the balance between antiapoptotic Bcl-2 and proapoptotic Bax and caspase-3 proteins plays a major role in regulating apoptosis (25,26). Overexpression of Bax and caspase-3 in cells leads to apoptotic death in response to apoptosis signals. In contrast, overexpression of Bcl-2 inhibits apoptosis and decreases the ROS formation and lipid peroxidation initiated by various stimuli (26). In pathological conditions, including MI, diabetes and stroke, the production of free radicals may override the scavenging effects of antioxidants, leading to oxidative stress (27). Thus, targeting myocardial apoptosis is a reasonable therapeutic strategy for reducing the risk of ischemic injury. It had been indicated that Bcl-2 inhibits the apoptosis induced by ROS through an antioxidative pathway (25). Analysis of the expression and regulation of Bcl-2 family proteins may provide insight as to their role in ischemia-induced apoptosis and stress adaptation. The present study observed that GXSTC treatment increased Bcl-2 protein expression during MI, as determined by western blot analysis.

Systematic reviews have shown that oxidative stress may powerfully induce programmed cell death. ROS are implicated in myocardial hypertrophy, apoptosis, contractile dysfunction and fibrosis (28). Increases in NADPH oxidase activity, oxidative stress and myocyte apoptosis have been observed concurrently in failing hearts (29). In cardiac myocytes, the *in vitro* inhibition of NADPH oxidase reduces apoptosis. NADPH oxidase subunits, gp91phox, p22phox, p47phox, p67phox and rac1, have been found to be expressed in endothelial cells, vascular smooth muscle cells, cardiomyocytes and fibroblasts (30). The increased expression of NADPH oxidase subunits, gp91phox and p22phox, has been associated with lipid peroxidation levels following acute MI in rats (31). The present study shows that GXSTC is able to reduce the increased protein and mRNA expression of NADPH oxidase subunits and oxidative stress associated with remote infarct myocardium in rats. In response to the treatment, the animals’ natural defensive system was activated to cope with the unwanted and toxic species, including increased production of SOD, GSH and CATA. The present study indicates that orally administered GXSTC possesses antioxidative properties. The results are consistent with those of a previous study demonstrating that NADPH oxidase activation mediates ROS production in cardiac hypertrophy and failure (3,30), which is also implicated in myocyte apoptosis.

In conclusion, the present study demonstrates that GXSTC has significant cardioprotective effects against ischemic myocardial injury in rats, which is likely to be due to its antioxidant and antiapoptotic properties. Therefore, GXSTC...
may be used as an effective and promising medicine for the prophylaxis and treatment of IHD.

Acknowledgements
The study was supported by a grant from the Ministry of National Science and Technology during the Significant New Drugs Creation Special Project (no. 2011ZX09401-308-6).

References
1. Marzilli M, Affinito S and Focardi M: Changing scenario in chronic ischemic heart disease: therapeutic implications. Am J Cardiol 98: 33-72, 2006.
2. Razavi HM, Hamilton JA and Fong Q: Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 104: 147-162, 2005.
3. Kumar D, Lou H and Singal PK: Oxidative stress and apoptosis in heart dysfunction. Herz 27: 662-668, 2002.
4. Qin F, Simeone M and Patel R: Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 43: 271-281, 2007.
5. Qin F, Liu YX, Zhao HW, Huang X, Ren P and Zhu ZY: Chinese medicinal formula Guan-Xin-Er-Hao protects the heart against oxidative stress induced by acute ischemic myocardial injury in rats. Phytomedicine 16: 215-221, 2009.
6. Matkowski A, Zieleńska S, Oszmiański J and Lamer-Zarawski E: Antioxidant activity of extracts from leaves and roots of Salvia miltiorrhiza Bunge, S. przewalskii Maxim., and S. verticillata L. Bioreossur Technol 99: 7892-7896, 2008.
7. Takemura G and Fujiwara H: Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 104: 1-16, 2004.
8. Singal PK, Khaber N, Palace V and Kumar D: The role of oxidative stress in the genesis of heart disease. Cardiovasc Res 40: 426-432, 1998.
9. Hao Y, Yao TM, Liang Z, Li J, You Y and Han YL: Effects of Guanxin Shoutong capsule on lipid metabolism and hemorhoeoe in rat model with experimental atherosclerosis. Journal of Liaoning University of TCM 13: 248-250, 2011 (In Chinese).
10. Lee KG and Shibamoto T: Antioxidant property of aroma extract isolated from clove buds (Syzygium aromaticum (L.) Merr. et Perryl. Food Chem 74: 443-448, 2001.
11. Qi JX, Zhao L, Kong LG, Wang ML, Wang P, Ren J and Wang L: Influence of Guanxin Shoutong containing serum on vascular smooth muscle cells proliferation induced by advanced glycation end products. Pharmacology and Clinics of Chinese Medica 28: 155-158, 2012 (In Chinese).
12. Lam FF, Yeung JH, Chan KM and Or PM: Dihydrotanshinone, a lipophilic component of Salvia miltiorrhiza (danshen), relaxes rat coronary artery by inhibition of calcium channels. J Ethnopharmacol 119: 318-321, 2008.
13. Zhou X, Chan SW, Tseng HL, Deng Y, Hoi PM, Choi PS, Or PM, Yang JM, Lam FF, Lee SM, et al: Danshensu is the major marker for the antioxidant and vasorelaxation effects of Danshen (Salvia miltiorrhiza) water-extracts produced by different heat water-extractions. Phytomedicine 19: 1263-1269, 2012.
14. Zhang Y, He L, Meng L, Luo W and Xu X: Suppression of tumor-induced angiogenesis by taspine isolated from Radix et Rhizoma Leontics and its mechanism of action in vitro. Cancer Lett 262: 103-113, 2008.
15. Zhou Y, Luo W, Zheng L, Li M and Zhang Y: Construction of recombinant FGFR1 containing full-length gene and its potential application. Plasmid 64: 60-67, 2010.
16. Zhang YM, Dai BL, Zheng L, Zhan YZ, Zhang J, Smith WW, Wang XL, Chen YN and He LC: A novel angiogenesis inhibitor impairs lwo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation. Cell Death Dis 3: e406, 2012.
17. Li GL and li LX: Efficacy of Guanxin Shoutong Capsules for Treatment of Chronic Seable Angina. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease 10: 1041-1042, 2012.
18. Zheng L, He X, Ma W, Dai B, Zhan Y and Zhang Y: Tai722, an anti-angiogenesis inhibitor targeted on VEGFR-2 against human hepatoma. Biomed Pharmacother 66: 499-505, 2012.
19. Wu L, Qiao H, Li Y and Li L: Protective roles of puerarin and Danshensu on acute ischemic myocardial injury in rats. Phytomedicine 14: 652-658, 2007.
20. Biestlada L, Pietrzak Z, Brocka U, Oszuskowski P and Kramoski G: Markers of oxidative stress in pregnancies complicated by pregnancy induced hypertension and intrahepatic cholestasis. Ginekol Pol 78: 956-960, 2007 (In Polish).
21. Marnett LJ: Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 424: 83-95, 1999.
22. Zheng W, Huang LZ, Zhao L, Wang B, Xu HB, Wang GY, Wang ZL and Zhou H: Superoxide dismutase activity and malondialdehyde level in plasma and morphological evaluation of acute severe hemorrhagic shock in rats. Am J Emerg Med 26: 54-58, 2008.
23. Circu ML and Aw TY: Glutathione and modulation of cell apoptosis. Biochim Biophys Acta 1823: 1767-1777, 2012.
24. Wattanapitayakul SK and Bauer JA: Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol Ther 89: 187-206, 2001.
25. Neuss M, Crow MT, Chesley A and Lakatta EG: Apoptosis in cardiovascular disease - what is it - how does it occur. Cardiovasc Drugs Ther 15: 507-523, 2001.
26. Sorensen CM: Bcl-2 family members and disease. Biochim Biophys Acta 1644: 169-177, 2004.
27. Dhalla AK, Hill MF and Singal PK: Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 28: 506-514, 1996.
28. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS and Sawyer DB: Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282: C926-C934, 2002.
29. Brandes RP, Weissmann N and Schröder K: NADPH oxidases in cardiovascular disease. Free Radic Biol Med 49: 687-706, 2010.
30. Fukui T, Yoshiyama M, Hanatani A, Omura T, Yoshikawa J and Abe Y: Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun 281: 1200-1206, 2001.
31. Pardo-Andreu GL, Barrios MF, Curti C, Hernández I, Merino N, Lemus Y, Martínez I, Riaño A and Delgado R: Protective effects of mangiferin, on iron-induced oxidative damage to rat serum and liver. Pharmacol Res 57: 79-86, 2008.